<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850394</url>
  </required_header>
  <id_info>
    <org_study_id>ID 01-53-06</org_study_id>
    <nct_id>NCT01850394</nct_id>
  </id_info>
  <brief_title>Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement</brief_title>
  <official_title>Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement; A Prospective Triple-blinded Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine 1) the effective dosage of intra-articular
      tranexamic acid injection for controlling blood loss and blood transfusion requirement in
      conventional total knee replacement, and 2) whether the blood loss reduction effect depended
      on the dose of tranexamic acid used.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perioperative Blood Loss</measure>
    <time_frame>5 days after surgery</time_frame>
    <description>Drainage blood loss measured by accumulating total drainage volume postoperatively
Calculated total blood loss measured by using specific formula and difference between hematocrit preoperatively and the fourth postoperative day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Hemoglobin Loss</measure>
    <time_frame>5 days after surgery</time_frame>
    <description>Total hemoglobin loos measured by difference between hemoglobin preoperatively and the fourth postoperative day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee Function Scores</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>Knee function score was measured with 2 methods, and were evaluated preoperatively and then postoperatively at 3-month, 6-month, and 1-year period.
Knee Society Knee Score using for rating knee function measurement and subdivided into two parts; knee score and function score 1.1. Knee score : calculated from pain, presence of deformity, total range of flexion, alignment, and stability. Total score is 100 (0-100), more score means better.
1.2. Function score : calculated from patient's ability to walk and climb stairs. The score ranges from 0-100, more score means better.
Western Ontario and McMaster Universities Arthritis Index or WOMAC score : a widely used, standardized questionnaires for evaluating the condition of patients with knee osteoarthritis, including pain (score = 0-20), stiffness (0-8), and functional limitation (0-68). Total score ranges from 0-68, lower score means better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Required Blood Transfusion</measure>
    <time_frame>postoperative period (5 days after surgery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Having Postoperative Complications</measure>
    <time_frame>postoperative 1-year period</time_frame>
    <description>Postoperative complications were measured as an incidence of the following complications;
wound hematoma
surgical site infection
systemic infection
deep vein thrombosis
pulmonary embolism
knee stiffness requiring manipulation
medical complication such as myocardial infarction, congestive hear failure</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Primary Osteoarthritis of Knee Nos</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>physiologic saline 25 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TXA-250 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A total of 25-ml solution with 250-mg tranexamic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TXA-500 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A total of 25-ml solution with 500-mg tranexamic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Inject tranexamic acid solution intra-articularly after fascia closure</description>
    <arm_group_label>TXA-250 group</arm_group_label>
    <arm_group_label>TXA-500 group</arm_group_label>
    <other_name>Transmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiologic saline</intervention_name>
    <description>Use physiologic saline for mixing with tranexamic acid or use alone in placebo group</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>TXA-250 group</arm_group_label>
    <arm_group_label>TXA-500 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients diagnosed as primary knee osteoarthritis and underwent unilateral primary
             cemented conventional total knee replacement

          -  no risk of abnormal bleeding tendency or bleeding disorder (normal coagulogram, serum
             creatinine &lt; 2.0 mg/dL, stop nonsteroidal anti-inflammatory drugs and antiplatelet
             drugs more than 7 days

          -  no contra-indication for tranexamic acid use (no active intravascular clotting
             process, no acquired defective colour vision, no subarachnoid hemorrhage, no
             hypersensitivity to TXA, and no any of history of serious adverse effects, thrombotic
             disorder and hematuria)

        Exclusion Criteria:

          -  incomplete data collection, for example, malfunctioned drain or accidental drain
             removal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Sa-Ngasoongsong P, Channoom T, Kawinwonggowit V, Woratanarat P, Chanplakorn P, Wibulpolprasert B, Wongsak S, Udomsubpayakul U, Wechmongkolgorn S, Lekpittaya N. Postoperative blood loss reduction in computer-assisted surgery total knee replacement by low dose intra-articular tranexamic acid injection together with 2-hour clamp drain: a prospective triple-blinded randomized controlled trial. Orthop Rev (Pavia). 2011;3(2):e12. doi: 10.4081/or.2011.e12. Epub 2011 Jun 29.</citation>
    <PMID>22053253</PMID>
  </reference>
  <reference>
    <citation>Ishida K, Tsumura N, Kitagawa A, Hamamura S, Fukuda K, Dogaki Y, Kubo S, Matsumoto T, Matsushita T, Chin T, Iguchi T, Kurosaka M, Kuroda R. Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty. Int Orthop. 2011 Nov;35(11):1639-45. doi: 10.1007/s00264-010-1205-3. Epub 2011 Jan 21.</citation>
    <PMID>21253725</PMID>
  </reference>
  <reference>
    <citation>Wong J, Abrishami A, El Beheiry H, Mahomed NN, Roderick Davey J, Gandhi R, Syed KA, Muhammad Ovais Hasan S, De Silva Y, Chung F. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am. 2010 Nov 3;92(15):2503-13. doi: 10.2106/JBJS.I.01518.</citation>
    <PMID>21048170</PMID>
  </reference>
  <reference>
    <citation>Maniar RN, Kumar G, Singhi T, Nayak RM, Maniar PR. Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients. Clin Orthop Relat Res. 2012 Sep;470(9):2605-12. doi: 10.1007/s11999-012-2310-y. Epub 2012 Mar 15.</citation>
    <PMID>22419350</PMID>
  </reference>
  <reference>
    <citation>Roy SP, Tanki UF, Dutta A, Jain SK, Nagi ON. Efficacy of intra-articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2012 Dec;20(12):2494-501. doi: 10.1007/s00167-012-1942-5. Epub 2012 Mar 15.</citation>
    <PMID>22419263</PMID>
  </reference>
  <reference>
    <citation>Seo JG, Moon YW, Park SH, Kim SM, Ko KR. The comparative efficacies of intra-articular and IV tranexamic acid for reducing blood loss during total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2013 Aug;21(8):1869-74. doi: 10.1007/s00167-012-2079-2. Epub 2012 Jun 24. Erratum in: Knee Surg Sports Traumatol Arthrosc. 2013 Aug;21(8):1875.</citation>
    <PMID>22729012</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2013</study_first_submitted>
  <study_first_submitted_qc>May 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <results_first_submitted>May 9, 2013</results_first_submitted>
  <results_first_submitted_qc>October 24, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2013</results_first_posted>
  <last_update_submitted>October 24, 2013</last_update_submitted>
  <last_update_submitted_qc>October 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Viroj Kawinwonggowit</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The patients, who planned to undergo primary total knee replacement, were recruited from medical clinics before setting the operative schedule between 2009 and 2010.</recruitment_details>
      <pre_assignment_details>Seventeen patients were excluded that including refusal to participate (4 patients), serum creatinine more than 2.0 mg% (4 patients), rheumatoid arthritis (4 patients), abnormal coagulogram (3 patients), and history of stroke (2 patients)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>physiologic saline 25 ml
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group</description>
        </group>
        <group group_id="P2">
          <title>TXA-250 Group</title>
          <description>A total of 25-ml solution with 250-mg tranexamic acid
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Tranexamic Acid : Inject tranexamic acid solution intra-articularly after fascia closure</description>
        </group>
        <group group_id="P3">
          <title>TXA-500 Group</title>
          <description>A total of 25-ml solution with 500-mg tranexamic acid
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Tranexamic Acid : Inject tranexamic acid solution intra-articularly after fascia closure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>physiologic saline 25 ml
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group</description>
        </group>
        <group group_id="B2">
          <title>TXA-250 Group</title>
          <description>A total of 25-ml solution with 250-mg tranexamic acid
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Tranexamic Acid : Inject tranexamic acid solution intra-articularly after fascia closure</description>
        </group>
        <group group_id="B3">
          <title>TXA-500 Group</title>
          <description>A total of 25-ml solution with 500-mg tranexamic acid
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Tranexamic Acid : Inject tranexamic acid solution intra-articularly after fascia closure</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="135"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.2" spread="7.3"/>
                    <measurement group_id="B2" value="67.6" spread="8.7"/>
                    <measurement group_id="B3" value="68.1" spread="6.2"/>
                    <measurement group_id="B4" value="67.3" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Perioperative Blood Loss</title>
        <description>Drainage blood loss measured by accumulating total drainage volume postoperatively
Calculated total blood loss measured by using specific formula and difference between hematocrit preoperatively and the fourth postoperative day</description>
        <time_frame>5 days after surgery</time_frame>
        <population>Using intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>physiologic saline 25 ml
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group</description>
          </group>
          <group group_id="O2">
            <title>TXA-250 Group</title>
            <description>A total of 25-ml solution with 250-mg tranexamic acid
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Tranexamic Acid : Inject tranexamic acid solution intra-articularly after fascia closure</description>
          </group>
          <group group_id="O3">
            <title>TXA-500 Group</title>
            <description>A total of 25-ml solution with 500-mg tranexamic acid
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Tranexamic Acid : Inject tranexamic acid solution intra-articularly after fascia closure</description>
          </group>
        </group_list>
        <measure>
          <title>Perioperative Blood Loss</title>
          <description>Drainage blood loss measured by accumulating total drainage volume postoperatively
Calculated total blood loss measured by using specific formula and difference between hematocrit preoperatively and the fourth postoperative day</description>
          <population>Using intention-to-treat analysis</population>
          <units>ml</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Drainage blood loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="546.9" spread="273.0"/>
                    <measurement group_id="O2" value="475.0" spread="254.4"/>
                    <measurement group_id="O3" value="430.2" spread="224.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calculated total blood loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329.2" spread="119.4"/>
                    <measurement group_id="O2" value="239.7" spread="83.7"/>
                    <measurement group_id="O3" value="217.2" spread="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>180</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>300</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>150</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>200</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Knee Function Scores</title>
        <description>Knee function score was measured with 2 methods, and were evaluated preoperatively and then postoperatively at 3-month, 6-month, and 1-year period.
Knee Society Knee Score using for rating knee function measurement and subdivided into two parts; knee score and function score 1.1. Knee score : calculated from pain, presence of deformity, total range of flexion, alignment, and stability. Total score is 100 (0-100), more score means better.
1.2. Function score : calculated from patient’s ability to walk and climb stairs. The score ranges from 0-100, more score means better.
Western Ontario and McMaster Universities Arthritis Index or WOMAC score : a widely used, standardized questionnaires for evaluating the condition of patients with knee osteoarthritis, including pain (score = 0-20), stiffness (0-8), and functional limitation (0-68). Total score ranges from 0-68, lower score means better.</description>
        <time_frame>1 year after surgery</time_frame>
        <population>Using intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>physiologic saline 25 ml
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group</description>
          </group>
          <group group_id="O2">
            <title>TXA-250 Group</title>
            <description>A total of 25-ml solution with 250-mg tranexamic acid
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Tranexamic Acid : Inject tranexamic acid solution intra-articularly after fascia closure</description>
          </group>
          <group group_id="O3">
            <title>TXA-500 Group</title>
            <description>A total of 25-ml solution with 500-mg tranexamic acid
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Tranexamic Acid : Inject tranexamic acid solution intra-articularly after fascia closure</description>
          </group>
        </group_list>
        <measure>
          <title>Knee Function Scores</title>
          <description>Knee function score was measured with 2 methods, and were evaluated preoperatively and then postoperatively at 3-month, 6-month, and 1-year period.
Knee Society Knee Score using for rating knee function measurement and subdivided into two parts; knee score and function score 1.1. Knee score : calculated from pain, presence of deformity, total range of flexion, alignment, and stability. Total score is 100 (0-100), more score means better.
1.2. Function score : calculated from patient’s ability to walk and climb stairs. The score ranges from 0-100, more score means better.
Western Ontario and McMaster Universities Arthritis Index or WOMAC score : a widely used, standardized questionnaires for evaluating the condition of patients with knee osteoarthritis, including pain (score = 0-20), stiffness (0-8), and functional limitation (0-68). Total score ranges from 0-68, lower score means better.</description>
          <population>Using intention-to-treat analysis</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Knee Society Knee score at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.9" spread="10.1"/>
                    <measurement group_id="O2" value="151.2" spread="9.1"/>
                    <measurement group_id="O3" value="150.9" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC score at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="6.6"/>
                    <measurement group_id="O2" value="15.1" spread="6.2"/>
                    <measurement group_id="O3" value="14.5" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>140</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Required Blood Transfusion</title>
        <time_frame>postoperative period (5 days after surgery)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>physiologic saline 25 ml
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group</description>
          </group>
          <group group_id="O2">
            <title>TXA-250 Group</title>
            <description>A total of 25-ml solution with 250-mg tranexamic acid
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Tranexamic Acid : Inject tranexamic acid solution intra-articularly after fascia closure</description>
          </group>
          <group group_id="O3">
            <title>TXA-500 Group</title>
            <description>A total of 25-ml solution with 500-mg tranexamic acid
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Tranexamic Acid : Inject tranexamic acid solution intra-articularly after fascia closure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Required Blood Transfusion</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Having Postoperative Complications</title>
        <description>Postoperative complications were measured as an incidence of the following complications;
wound hematoma
surgical site infection
systemic infection
deep vein thrombosis
pulmonary embolism
knee stiffness requiring manipulation
medical complication such as myocardial infarction, congestive hear failure</description>
        <time_frame>postoperative 1-year period</time_frame>
        <population>Using Intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>physiologic saline 25 ml
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group</description>
          </group>
          <group group_id="O2">
            <title>TXA-250 Group</title>
            <description>A total of 25-ml solution with 250-mg tranexamic acid
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Tranexamic Acid : Inject tranexamic acid solution intra-articularly after fascia closure</description>
          </group>
          <group group_id="O3">
            <title>TXA-500 Group</title>
            <description>A total of 25-ml solution with 500-mg tranexamic acid
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Tranexamic Acid : Inject tranexamic acid solution intra-articularly after fascia closure</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Having Postoperative Complications</title>
          <description>Postoperative complications were measured as an incidence of the following complications;
wound hematoma
surgical site infection
systemic infection
deep vein thrombosis
pulmonary embolism
knee stiffness requiring manipulation
medical complication such as myocardial infarction, congestive hear failure</description>
          <population>Using Intention-to-treat analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Re-clamp incidence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Re-dressing incidence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Venous thromboembolic complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congestive heart failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Hemoglobin Loss</title>
        <description>Total hemoglobin loos measured by difference between hemoglobin preoperatively and the fourth postoperative day</description>
        <time_frame>5 days after surgery</time_frame>
        <population>Use intention-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>physiologic saline 25 ml
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group</description>
          </group>
          <group group_id="O2">
            <title>TXA-250 Group</title>
            <description>A total of 25-ml solution with 250-mg tranexamic acid
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Tranexamic Acid : Inject tranexamic acid solution intra-articularly after fascia closure</description>
          </group>
          <group group_id="O3">
            <title>TXA-500 Group</title>
            <description>A total of 25-ml solution with 500-mg tranexamic acid
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Tranexamic Acid : Inject tranexamic acid solution intra-articularly after fascia closure</description>
          </group>
        </group_list>
        <measure>
          <title>Total Hemoglobin Loss</title>
          <description>Total hemoglobin loos measured by difference between hemoglobin preoperatively and the fourth postoperative day</description>
          <population>Use intention-to-treat analysis</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.2"/>
                    <measurement group_id="O2" value="2.2" spread="0.7"/>
                    <measurement group_id="O3" value="2.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.66</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 days</time_frame>
      <desc>Perioperative venous thromboembolic complications
deep vein thrombosis screened with duplex doppler ultrasound in all cases
pulmonary embolism diagnosed with clinical hypoxemia and confirmed with computer tomography angiogram</desc>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>physiologic saline 25 ml
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group</description>
        </group>
        <group group_id="E2">
          <title>TXA-250 Group</title>
          <description>A total of 25-ml solution with 250-mg tranexamic acid
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Tranexamic Acid : Inject tranexamic acid solution intra-articularly after fascia closure</description>
        </group>
        <group group_id="E3">
          <title>TXA-500 Group</title>
          <description>A total of 25-ml solution with 500-mg tranexamic acid
Physiologic saline : Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
Tranexamic Acid : Inject tranexamic acid solution intra-articularly after fascia closure</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Venous thromboembolic complication</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Paphon Sa-ngasoongsong</name_or_title>
      <organization>Faculty of Medicine, Ramathibodi Hospital, Mahidol University</organization>
      <phone>66-2-2011589</phone>
      <email>chan3s@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

